
Raphael Mechoulam delivers a speech to participants at the CannaTech conference, an international summit for accelerating cannabis innovation, in the Israeli city of Tel Aviv on March 7, 2016. Mechoulam is a leading figure in the medical cannabis research and serves today as the chairperson of the CannaTech conference.
The compound in question was presented to the world in partnership with EPM, a global biotechnology company based in the U.S. that aims to bridge the gap between the cannabis and pharmaceutical industries.
Comment: That sounds like a possibly ominous partnership.
During a recent, exclusive conversation, CEO Reshef Swisa and Dr. Mechoulam, shared the history of the journey behind this revolutionary process and its significance in evolving the use of CBD as a pharmaceutical drug.














Comment: There are numerous naturally occurring compounds in cannabis that act synergistically and are yet to be fully understood. It may be that isolating and synthesizing one compound could impact the holistic effect and may ultimately be detrimental:
- "One of the most valuable medicines we possess": The Victorian doctor who promoted medical cannabis
- Hypocrites: UK is world's largest legal cannabis producer UN reveals - Claims it has "no therapeutic value"
- UK cannabis farm bought by US-based fund in $81 million deal
Also check out SOTT radio's: The Health & Wellness Show: The Highs and Lows of Cannabis as Medicine